Protection of Babesia bigemina-immune animals against subsequent challenge with virulent Babesia bovis

Wright, I.G.; Goodger, B. V.; Leatch, G.; Aylward, James; Rode-Bramanis, K.; Waltisbuhl, D.J.

doi:10.1128/iai.55.2.364-368.1987

Cited by 36 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 42,000-molecular-weight Mexico B. bovis protein, which was highly immunogenic in immunoprecipitations with C151 antiserum, was precipitated by all five of the undiluted and three of the diluted Honduras antisera. The presence and possible functional importance of species-cross-reactive epitopes between B. bigemina and B. bovis and the relative molecular weights of several proteins bearing these epitopes have been previously reported (1, 20,23). By using radiolabeled antigen and immunoprecipitation, additional B. bigemina and B. bovis proteins with speciescross-reactive epitopes have been identified in this study.…”

supporting

confidence: 65%

Identification of Babesia bigemina and Babesia bovis merozoite proteins with isolate- and species-common epitopes recognized by antibodies in bovine immune sera

et al. 1988

View full text Add to dashboard Cite

Immunoprecipitation of radiolabeled antigens with bovine antisera indicated that many Babesia bigemina and Babesia bovis merozoite proteins contain isolate-common epitopes, while at least 16 B. bigemina and 8 B. bovis proteins contain species-cross-reactive epitopes. One immunogenic, isolate-common, and species-specific candidate diagnostic protein from each species was identified. Bovine babesiosis caused by Babesia bigemina and Babesia bovis continues to be a significant deterrent to livestock production in countries with tropical or subtropical climates (17). Observations made in studies on immunoprophylaxis against and diagnosis of these parasites have indicated that there are antigenic similarities and differences between the two species (1, 6, 7, 10, 13, 14, 20, 22, 23), as well as among various isolates of the same species (1-4, 8, 9, 15, 16, 18, 19, 21), that may have important functional roles in the induction of protective immunity and antibody-based diagnosis. In this report, the identification, relative immunogenicity, and isolate or species cross-reactivity of biosynthetically radiolabeled, Mexico isolate B. bigemina and B. bovis merozoite proteins immunoprecipitated by bovine immune sera are described. Antisera B85 and C151, which were used for immunoprecipitations, were collected from cattle with intact spleens 25 (B85) and 60 (C151) days after experimental infection with cryopreserved (12, 18) Mexico isolate blood stabilates of B. bigemina and B. bovis, respectively. Heterologous B. bovis isolate antisera (provided by J. L. Zaugg, Animal Disease Research Unit, U.S. Department of Agriculture, Caldwell, Idaho) were collected from cattle in Honduras that had recovered from tick-induced field infection with a native B. bovis isolate.

show abstract

supporting

confidence: 65%

Identification of Babesia bigemina and Babesia bovis merozoite proteins with isolate- and species-common epitopes recognized by antibodies in bovine immune sera

et al. 1988

View full text Add to dashboard Cite

show abstract

“…These results are in agreement with results previously described for B. bovis and B. bigemina isolates (6,11,14,16,22). Similarly, cross-antigenicity and cross-protection between different Babesia species is well documented: for example, B. bovis and B. bigemina (19,23,29), B. rhodaini and B. microti (3), and B. bigemina and B. major (31). This extensive cross-immunogenicity suggests the conservation of several epitopes between babesial antigens from different isolates.…”

Section: Discussionmentioning

confidence: 99%

Analysis of immune responses of different hosts to Babesia divergens isolates from different geographic areas and capacity of culture-derived exoantigens to induce efficient cross-protection

et al. 1991

View full text Add to dashboard Cite

The immunoprecipitation of [35S]methionine-radiolabelled antigens from different Babesia divergens isolates by using bovine, gerbil, and human immune sera has shown that many B. divergens proteins contain epitopes shared between isolates. The cross-protective capacity of culture-derived soluble immunogens from the B. divergens Rouen 1987 isolate was tested against different B. divergens isolates. Results showed complete protection against the 7107b French isolate and substantial protection against the Weybridge 8843 English isolate (80% protection) and the Munich 87 German isolate (60% protection). In order to explain these vaccination results and to assess both the common and variable antigenicity of B. divergens, the antigenic patterns of the challenge isolates (Rouen 1987, 7107b, Weybridge 8843, and Munich 87) were compared by immunoprecipitation, using gerbil antisera raised against the Rouen 1987 vaccine isolate. Differences in the antigenic patterns and in the cross-protection of gerbils in these heterologous challenges were examined by studying the virulence and the antigenic status of each isolate.

show abstract

“…Immunity to heterologous challenge Cattle recovered from B bigemina infections show some resistance to B bovis challenge, 37 but the reverse is not true and the degree of protection is seldom adequate. It is assumed that similar immune mechanisms to B bovis exist in B bigemina outbreak with the same vaccine strain.…”

Section: Immunity To Babesia Bigeminamentioning

confidence: 99%

Immunity following use of Australian tick fever vaccine: a review of the evidence

Bock

Vos

2001

Aust Veterinary J

View full text Add to dashboard Cite

Objective To review the evidence available on the degree and duration of immunity provided by Australian tick fever vaccines against Babesia bovis, B bigeminaand Anaplasma marginale infections in Australia and overseas. Background Vaccines containing attenuated strains of B bovis and B bigemina as well as A centrale grown in splenectomised calves have been used in Australia since 1964 to immunise cattle against tick fever. About 800,000 doses of vaccine are supplied annually and much of the evidence for protection is field evidence rather than conventional immunological measures or pen trials. Conclusions Immunity to Babesia bovis and B bigemina – A single inoculation generally provides sound, long‐lasting protection both in Australia and overseas. No evidence was found of a loss of immunity with time. Vaccine failures to B bovis d o occur, but are uncommon and evidently caused by a number of factors, including immune responsiveness of the vaccinated animals, and immunogenicity of the vaccine strain. Immunity to Anaplasma marginale– The vaccine containing A centrale provides partial, variable protection against A marginale. Protection against challenge in Australia is adequate in most cases to prevent disease and use of the vaccine in this country appears to be justified. Protection against antigenically diverse, highly virulent stocks of A marginale i n other countries is, at times, clearly inadequate and better vaccines are required in situations where the challenge is severe.

show abstract

Protection of Babesia bigemina-immune animals against subsequent challenge with virulent Babesia bovis

Cited by 36 publications

References 15 publications

Identification of Babesia bigemina and Babesia bovis merozoite proteins with isolate- and species-common epitopes recognized by antibodies in bovine immune sera

Identification of Babesia bigemina and Babesia bovis merozoite proteins with isolate- and species-common epitopes recognized by antibodies in bovine immune sera

Analysis of immune responses of different hosts to Babesia divergens isolates from different geographic areas and capacity of culture-derived exoantigens to induce efficient cross-protection

Immunity following use of Australian tick fever vaccine: a review of the evidence

Contact Info

Product

Resources

About